Discovery on Target 2025

Meet our experts at the 23rd Annual Discovery on Target focused on novel drug targets and technologies. The symposium will spotlight advancements in both current and emerging fields, with a focus on target validation strategies for the discovery and development of innovative therapeutic agents from biologics to small molecules.

Organized by CHI, Discovery on Target 2025 will cover cancer therapies, protein degradation, induced proximity, AI/machine learning, membrane proteins, translational models, synthetic biology, and other relevant topics.

“Identification of a submicromolar BRD4 PROTAC degrader from a moderately potent DEL Hit: harnessing the synergy of DEL and PROTAC technologies”

Viviane Brel, VP Pharmacology, will present the development of a submicromolar BRD4 PROTAC directly derived from a moderately potent DEL hit, showcasing the synergy between DEL and PROTAC technologies in targeted protein degradation.
Do not miss her poster presentation on the afternoon of September 24 and September 25, see Poster #B35.

Abstract:
We identified a BRD4-targeting PROTAC degrader with submicromolar degradation potency derived directly from a moderately potent hit identified via a DNA-encoded library (DEL) screen using our NovaDEL platform. This underscores the potential of PROTACs to achieve efficient degradation from micromolar binders, a concept rarely demonstrated. This finding reinforces the viability of leveraging such binders in induced proximity strategies and opens new avenues for therapeutic innovation and drug discovery.

Join us on our booth No. 508

If you are attending, do not miss the poster sessions and come and discuss your projects in drug discovery on our booth number 508. Just set up a meeting!